McKesson (MCK) stock has been in focus after a recent 2.09% decline, as investors weighed softer quarterly results against index additions, expanded partnerships and the company’s continued tilt toward higher margin healthcare segments.

Over the past year, McKesson’s share price return has been mixed. A recent 4.52% one-month gain contrasts with a 13.14% decline over three months and a 6.73% fall year to date. Total shareholder return over 1, 3 and 5 years of 9.32%, 85.92% and 315.68% respectively points to momentum that has built over longer periods as investors reassess growth prospects and risk after softer quarterly numbers, expanded partnerships and fresh inclusion in Russell 1000 defensive indexes.

If McKesson’s role in healthcare infrastructure has your attention, it can be useful to widen the lens and look at other companies exposed to similar themes, including those leaning into medical AI. One way to do that is by scanning 39 healthcare AI stocks

With McKesson now trading around $768 after recent volatility, a value score of 4 and a sizeable gap to the average analyst price target, you have to ask: is there still upside on the table, or is the market already baking in future growth?

Most Popular Narrative: 18.4% Undervalued

With McKesson last closing at $768.06 against a narrative fair value of $941.40, the current price sits well below what this widely followed view implies.

Increasing adoption of specialty and oncology pharmaceuticals, alongside recent acquisitions (Core Ventures and PRISM Vision) that expand the provider network and service portfolio, are improving revenue mix quality and positioning the company for higher operating margins and earnings growth.

Want to see what sits behind that margin story? The narrative leans on steady top line expansion, firm profitability and a richer earnings multiple than today. The exact mix of growth, margins and valuation expectations might surprise you.

Result: Fair Value of $941.40 (UNDERVALUED)

However, McKesson’s story can change quickly if regulatory pressure on drug pricing intensifies or if vertical integration reduces its role in the pharmaceutical supply chain.

Another View on McKesson’s valuation

The analyst narrative frames McKesson as about 18.4% undervalued at $768, using earnings forecasts and a target P/E of 20.7x. Yet on today’s numbers, McKesson trades on 18.9x P/E versus a fair ratio of 29.5x, the US Healthcare industry at 25.6x and peers at 23.8x. This implies a wide valuation gap that could either mark opportunity or signal that the market is pricing in real balance sheet and policy risks.

To see how that earnings based view stacks up against a full cash flow model, it is worth looking at how the SWS DCF model treats McKesson’s future cash generation and discount rate assumptions, and where that leaves the estimated value per share relative to today’s $768 price. See what the numbers say about this price — find out in our valuation breakdown.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out McKesson for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 41 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment on McKesson split between risks and rewards, it helps to move quickly, review the data directly and form your own stance by weighing the 5 key rewards and 1 important warning sign

Looking for more investment ideas beyond McKesson?

If McKesson has sharpened your focus on quality and pricing power, do not stop here. Broaden your watchlist with other ideas that might fit your style.

• Target stronger long term compounding by scanning companies that look mispriced on fundamentals with the 41 high quality undervalued stocks
• Prioritise resilience and cash returns by reviewing companies known for robust payouts in the 8 dividend fortresses
• Stay ahead of the crowd by hunting potential future leaders using the screener containing 19 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.